Univercells Technologies

The next generation of biomanufacturing

Pune, India, 20-22 October 2022
Univercells Technologies was launched at the initiative of two global groups to deliver intensified & integrated platforms enabling access to life-saving therapies

Univercells Technologies’ genesis

Univercells Biologics for all
Making biologics affordable and available to all

Designing and delivering the next evolution of biomanufacturing
Global provider of innovative biomanufacturing technologies to achieve cost-effective advanced therapies production from R&D to commercial scales

Source: Univercells Technologies
An intensified & integrated portfolio of innovative biomanufacturing solutions, from R&D to commercial scales

The scale-X™ product range and the NevoLine™ Upstream platform

Source: Univercells Technologies
The NevoLine Upstream platform offers an integrated & automated solution for intensified industrial-scale vaccine manufacturing

NevoLine Upstream platform

1. Cell culture & viral production
2. Clarification I
3. Tangential Flow Filtration
4. Clarification II

Flexible by design
- Accommodates a range of single-use configurations tailored to the process design

Increased reliability
- Automated process reduces the number of manual interventions and risks of operator-related errors

Scalable solutions
- Representative scale-down models available to streamline process development

Large capacity in a compact system
- Delivers high productivity per cleanroom surface with significant operating cost savings

Source: Univercells Technologies
The NevoLine Upstream platform enables high viral throughput with a dramatically reduced footprint.

NevoLine Upstream vs packed-bed bioreactor | Upstream manufacturing footprint reduction

> Process intensification and chaining to replace multiple "stand-alone" bulky unit operations

> Dramatically reduce footprint of operations

> 3-fold reduction of equipment and cleanroom footprint

Source: Univercells Technologies
The **NevoLine Upstream** platform enables **high performance** in vaccine manufacture, reaching millions of doses per year.

### Vaccine production in the NevoLine Upstream platform

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dose size</th>
<th>Unit</th>
<th>200 m²</th>
<th>600 m²</th>
<th>200 m²</th>
<th>600 m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>rVSV- LASV</td>
<td>2.00E+07</td>
<td>PFU</td>
<td>&gt;11M</td>
<td>&gt;34M</td>
<td>228M</td>
<td>684M</td>
</tr>
<tr>
<td>sIPV</td>
<td>58.00</td>
<td>DU (trivalent)</td>
<td>&gt;150k</td>
<td>&gt;0.5M</td>
<td>&gt;3.5M</td>
<td>&gt;11M</td>
</tr>
<tr>
<td>VSV- Ebola</td>
<td>2.00E+07</td>
<td>PFU</td>
<td>&gt;100k</td>
<td>&gt;300k</td>
<td>&gt;2M</td>
<td>&gt;6M</td>
</tr>
<tr>
<td>nOPV</td>
<td>2.00E+05</td>
<td>TCID50</td>
<td>85M</td>
<td>255M</td>
<td>&gt;1.5B</td>
<td>&gt;5B</td>
</tr>
</tbody>
</table>

Source: Univercells Technologies
Thank you for your attention
www.univercellstech.com